Literature DB >> 20075715

Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil?

Raafat A El-Awady1, Ekram M Saleh, Jochen Dahm-Daphi.   

Abstract

Inhibition of the repair of 5-fluorouracil (FU)-induced DNA lesions may improve the response of many tumors to this anticancer agent. Despite the identified associations between DNA strand breaks and the lethality of thymidylate synthase inhibitors, the role of DNA double-strand break (DSB) repair pathways in a cellular response to 5-FU treatment has not been studied yet. Isogenic cell lines defective (irs1SF), wild type (AA8), or reconstituted (1SFK8) in the DSB repair protein XRCC3 were used to investigate the effect of defective DSB repair on the overall sensitivity of cells to 5-FU and to see how targeting DSB repair may affect other cellular responses to 5-FU. Treatment with 5-FU resulted in (i) similar induction of DSB in both cell lines as indicated by the formation of gamma-H2AX (a marker for DSB). The repair of these breaks was complete in AA8 but not in irs1SF cells. (ii) Concentration-dependent reduction in the survival of both cell lines. The AA8 cells were six times more sensitive to 5-FU than the irs1SF cells. (iii) An earlier and more prolonged G(1)/S phase arrest in AA8 compared with the irs1SF cells. (iv) Induction of apoptosis as indicated by sub-G(1) cells and caspase-3 activity in AA8 but not in irs1SF cells. XRCC3 complementation of irs1SF cells restored the wild-type phenotype. This result shows that targeting DSB repair is not always associated with increased sensitivity to DNA damaging agents such as 5-FU because it may affect other cellular responses such as cell cycle regulation and induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20075715     DOI: 10.1097/CAD.0b013e328334b0ae

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  10 in total

1.  Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine.

Authors:  Michael M Im; Sheryl A Flanagan; Jeffrey J Ackroyd; Donna S Shewach
Journal:  Radiat Res       Date:  2015-01-07       Impact factor: 2.841

2.  Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.

Authors:  Amelia M Huehls; Jill M Wagner; Catherine J Huntoon; Liyi Geng; Charles Erlichman; Anand G Patel; Scott H Kaufmann; Larry M Karnitz
Journal:  Cancer Res       Date:  2011-05-25       Impact factor: 12.701

3.  Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types.

Authors:  Cijo George Vazhappilly; Ekram Saleh; Wafaa Ramadan; Varsha Menon; Aya Mudhafar Al-Azawi; Hamadeh Tarazi; Hajjaj Abdu-Allah; Abdel-Nasser El-Shorbagi; Raafat El-Awady
Journal:  Invest New Drugs       Date:  2018-06-27       Impact factor: 3.850

4.  Antagonism between curcumin and the topoisomerase II inhibitor etoposide: a study of DNA damage, cell cycle regulation and death pathways.

Authors:  Ekram M Saleh; Raafat A El-awady; Nadia A Eissa; Wael M Abdel-Rahman
Journal:  Cancer Biol Ther       Date:  2012-08-16       Impact factor: 4.742

5.  Predictive markers for the response to 5-fluorouracil therapy in cancer cells: Constant-field gel electrophoresis as a tool for prediction of response to 5-fluorouracil-based chemotherapy.

Authors:  E M Saleh; R A El-Awady; N Anis
Journal:  Oncol Lett       Date:  2012-10-11       Impact factor: 2.967

Review 6.  DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.

Authors:  Amina Jamal Laham; Maha Saber-Ayad; Raafat El-Awady
Journal:  Cell Mol Life Sci       Date:  2020-09-01       Impact factor: 9.261

7.  Inhibition of exosome release by ketotifen enhances sensitivity of cancer cells to doxorubicin.

Authors:  Farman Matloob Khan; Ekram Saleh; Hussain Alawadhi; Rania Harati; Wolfram-Hubertus Zimmermann; Raafat El-Awady
Journal:  Cancer Biol Ther       Date:  2017-12-15       Impact factor: 4.742

8.  Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.

Authors:  Liyi Geng; Amelia M Huehls; Jill M Wagner; Catherine J Huntoon; Larry M Karnitz
Journal:  PLoS One       Date:  2011-12-15       Impact factor: 3.240

9.  Effect of safranal on the response of cancer cells to topoisomerase I inhibitors: Does sequence matter?

Authors:  Lama Lozon; Ekram Saleh; Varsha Menon; Wafaa S Ramadan; Amr Amin; Raafat El-Awady
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

10.  Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus.

Authors:  Tomonori Nakanoko; Hiroshi Saeki; Masaru Morita; Yuichiro Nakashima; Koji Ando; Eiji Oki; Takefumi Ohga; Yoshihiro Kakeji; Yasushi Toh; Yoshihiko Maehara
Journal:  Ann Surg Oncol       Date:  2013-09-25       Impact factor: 5.344

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.